ALMS
AlumisยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ALMS
Alumis Inc.
A clinical-stage biopharmaceutical company focused on developing oral therapeutics for the treatment of immune-mediated diseases
280 East Grand Avenue South San Francisco, California 94080
--
Alumis Inc., a Delaware corporation, was incorporated on January 29, 2021. They are a clinical-stage biopharmaceutical company initially focused on developing two tyrosine kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor they are developing to achieve maximum targeted inhibition, and A-005, a central nervous system osmotic molecule. The company's mission is to significantly improve patients' lives by replacing broad immunosuppression with targeted therapy.
Company Financials
EPS
ALMS has released its 2025 Q3 earnings. EPS was reported at -1.06, versus the expected -1, missing expectations. The chart below visualizes how ALMS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ALMS has released its 2025 Q3 earnings report, with revenue of 2.07M, reflecting a YoY change of NaN%, and net profit of -110.75M, showing a YoY change of -18.94%. The Sankey diagram below clearly presents ALMS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
